Hypertension in Pregnancy and Future Cardiovascular Disease Risk: A Narrative Review of Endothelial Dysfunction Pathways, Inter-Pregnancy Care Models, and Long-Term Surveillance
Abstract
Hypertensive Disorders of Pregnancy (HDP), including gestational hypertension and preeclampsia, are increasingly recognized not only as pregnancy-specific complications but also as early indicators of future cardiovascular disease (CVD). Women affected by HDP experience an elevated long-term burden of hypertension, ischemic heart disease, stroke, heart failure, and other cardiometabolic disorders, highlighting pregnancy as an important window for identifying previously unrecognized cardiovascular vulnerability. Endothelial dysfunction provides a plausible biological bridge between hypertensive pregnancy and subsequent cardiovascular disease. Abnormal placental angiogenic signaling, oxidative stress, systemic inflammation, and vascular injury can impair endothelial homeostasis during pregnancy, while incomplete vascular recovery after delivery may contribute to persistent arterial dysfunction and later cardiovascular pathology. This review explores current evidence linking HDP with long-term cardiovascular risk, emphasizing endothelial mechanisms that may underlie this transition. It further examines the inter-pregnancy period as a clinically important opportunity for cardiovascular risk assessment, blood pressure optimization, cardiometabolic management, lifestyle modification, and preconception counseling. Particular attention is given to integrated care models that connect obstetric services with primary and cardiovascular care beyond the immediate postpartum period. The review also evaluates approaches to long-term surveillance, including blood pressure, metabolic, renal, and vascular risk assessment, alongside emerging biomarker and digital monitoring strategies. Integrating pregnancy history into routine cardiovascular risk assessment may facilitate earlier identification of high-risk women and strengthen preventive care. Future research should prioritize standardized surveillance pathways, mechanism-informed risk stratification, and scalable models capable of sustaining cardiovascular prevention across the life course.